Xlife Sciences AG (XSWX:XLS) YoY EPS Growth: -170.07% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:XLS Xlife Sciences AG XSWX:XLS
52 GF Score
Price CHF16.80
GF Value CHF7.18
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG YoY EPS Growth?

Xlife Sciences AG XSWX:XLS -0.88% 52 YoY EPS Growth is -170.07% as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 52/100 and a GF Value™ of CHF7.18 (Significantly Overvalued). The stock has 10 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Xlife Sciences AG's YoY EPS Growth for the quarter that ended in Dec. 2025 was -170.07%.

Xlife Sciences AG's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was CHF-3.23.

Xlife Sciences AG YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG YoY EPS Growth Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial 140.56 -76.91 4.00 125.48 -180.17

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.62 107.27 44.97 -762.50 -170.07
XSWX:XLS
52GF Score
Xlife Sciences AG XSWX:XLS
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Xlife Sciences AG's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-3.76-4.69)/ | 4.69 |
=-180.17 %

Xlife Sciences AG's YoY EPS Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EPS Growth (Q: Dec. 2025 )
=(Earnings per Share (Diluted) (Q: Dec. 2025 )-Earnings per Share (Diluted) (Q: Dec. 2024 )) / | Earnings per Share (Diluted) (Q: Dec. 2024 )) |
=(-3.23-4.61)/ | 4.61 |
=-170.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -170.07% mean?
Xlife Sciences AG (XSWX:XLS) has a YoY EPS Growth of -170.07% as of Dec. 2025. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's YoY EPS Growth too high?
Xlife Sciences AG's current YoY EPS Growth is -170.07%. Overall, Xlife Sciences AG has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's YoY EPS Growth compare to VRTX and REGN?
Xlife Sciences AG's YoY EPS Growth of -170.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Xlife Sciences AG and its competitors. Xlife Sciences AG's current YoY EPS Growth is -170.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.18, compared to a current price of CHF16.80 — trading 134% above its estimated fair value. The current YoY EPS Growth is -170.07%. Xlife Sciences AG's overall GF Score™ is 52/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current YoY EPS Growth is -170.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF16.80 is trading 134% above its estimated GF Value™ of CHF7.18. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • YoY EPS Growth: -170.07%
  • GF Value™: CHF7.18 vs. price of CHF16.80 (134% above fair value)
  • GF Score™: 52/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
52GF Score

Get the complete analysis for XSWX:XLS

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF16.80
Price
CHF7.18
GF Value